Peter Cackett spoke to ophthalmologist and social media sensation Dr Glaucomflecken about his early days in comedy, the role satire can play in impacting medical governance, and where he might take his brand of medical comedy next. It was towards...
Professor James Morgan is an Ophthalmic Consultant at Cardiff Hospital and also the clinical director of the OpenEyes programme. Given the national push for electronic records we felt hearing directly from James would be of interest. The interview was conducted...
Can you give us a brief overview of the organisation and its hope for the future? Orbis International is a global non-governmental organisation (NGO) which is dedicated to the prevention of blindness. We’ve now been going since 1982. We’re very...
Part 1 of this topic can be found here There are currently no proven cures for inherited retinal disease (IRD). However, multiple avenues of research are being investigated to better understand disease mechanisms and trial potential therapies that may slow...
Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...
Orbis and partners mark historic 100-millionth dose of azithromycin antibiotics in the fight to eliminate blinding trachoma in Ethiopia by 2030. This milestone was achieved 20 years after Orbis began leading mass drug administrations.
In this paper the authors describe the growing use of computer-assisted surgery in ophthalmology. It is already described as a powerful adjunct in neurosurgery and sinus surgery and here they describe their experience of using it for the orbit; specifically...
This retrospective case series looks at the use of teprotumumab in nine patients with thyroid eye disease (TED) of clinical activity score ≤one and >nine months duration, in an American cohort. Current European guidelines have suggested the use of teprotumumab...
Leading eyecare charity Orbis and Nepal’s National Society of Comprehensive Eye Care (NNJS) have worked together since 2019 to implement a programme called REACH (Refractive Error Among Children) in Eastern Nepal.